AIG Hospitals to Launch ₹800 Crore Oncology Centre with South-East Asia’s First Dynamic ARC Proton Therapy

Qiagen Secures FDA Clearance for QIAstat-Dx Gastrointestinal Panel

Ovation.io Launches Groundbreaking GLP-1 Research Dataset to Advance Precision Medicine

Kotak Invests ₹940 Crore in Neuberg Diagnostics to Drive Expansion and IPO Preparation

NICE Recommends Olaparib for BRCA-Mutated Advanced Breast Cancer

SOPHiA GENETICS and Platomics Collaborate to Streamline IVDR Compliance for Clinical Labs

India Unveils Genome Sequencing Data of 10,000 Individuals: A Milestone in Biotechnology Research

Ambry Genetics Advances BRCA2 Variant Classification with CRISPR-Based Study Published in *Nature*

Geneoscopy Secures $105M Series C Funding to Advance Colorectal Cancer Screening

Vertex and Orna Partner to Develop In Vivo Gene Therapies for Blood Disorders

FDA Grants Priority Review to Dizal’s Sunvozertinib for EGFR Exon20ins NSCLC

MD Anderson and Myriad Genetics Forge Strategic Alliance to Advance MRD Testing in Cancer Care

Pillar Biosciences Partners with MSK to Enhance Precision Oncology with OncoKB™ Integration

CytoMed and SunAct Partner to Advance Allogeneic Gamma Delta T Cell Therapy in India

China’s NMPA Approves Astellas’ Zolbetuximab for Advanced Gastric and GEJ Cancer

Home
/
update
/
details

Caris Life Sciences Partners with ECOG-ACRIN to Advance Precision Medicine in Breast Cancer Research

NextEdge Admin

25 Oct 2024

2 min 28 sec

Caris Life Sciences® (Caris), a leading AI-driven TechBio and precision medicine company, announced a multi-year research collaboration with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). This partnership combines Caris' advanced genomic, transcriptomic, and proteomic profiling capabilities with ECOG-ACRIN’s extensive research expertise.

The collaboration’s first project will utilize tumor tissue samples from the TAILORx clinical trial, one of the largest breast cancer studies, designed to personalize treatment options. Supported by the National Cancer Institute (NCI), the trial focused on early-stage breast cancer, which accounts for 60% of the 310,720 new annual breast cancer cases in the U.S. Despite advancements that reduced mortality by 42% over the past three decades, racial disparities in breast cancer outcomes remain a concern, as highlighted in a TAILORx study published in *JAMA Surgery*.

Caris will conduct whole exome and transcriptome sequencing on tumor samples from nearly 10,000 TAILORx participants, who have been followed for over 11 years. The research aims to enhance risk prediction, identify recurrence patterns, and explore racial disparities using AI and machine learning tools. Data will be shared publicly in an NCI database after the project concludes.

ECOG-ACRIN’s membership in the Caris Precision Oncology Alliance™ further strengthens the collaboration, advancing molecular testing standards and expanding treatment options. “This joint effort represents a significant step in precision oncology,” said Peter J. O’Dwyer, MD, Group Co-Chair of ECOG-ACRIN. Caris CMO George W. Sledge, Jr., MD, noted the importance of building on TAILORx’s legacy, emphasizing the potential for even more personalized cancer care.